GLP-1 News & Updates
Daily summaries of the most important GLP-1 stories — FDA decisions, clinical research, telehealth updates, and insurance coverage changes.
Today — Tuesday, June 23, 2026
4 articlesEli Lilly gave extraordinary obesity drug access to a 79-year-old patient through compassionate use
TLDR: Eli Lilly and the FDA granted a 79-year-old patient access to retatrutide — an experimental obesity drug still in trials — through the FDA compassionate use program, which allows use of unapproved therapies when no comparable alternatives exist. The identity of the patient is drawing scrutiny, with STAT News reporting it was a notable individual whose access fell outside standard trial enrollment. The case puts a spotlight on how expanded access decisions are made for high-profile patients and whether the process is applied consistently.
Read full story →Pfizer berobenatide shows weight loss efficacy with monthly dosing in VESPER Phase 2b trials at ADA 2026
TLDR: Pfizer presented updated Phase 2b data for berobenatide at the American Diabetes Association 86th Scientific Sessions, showing the investigational GLP-1 agonist maintained weight loss after transitioning from weekly to once-monthly dosing. The 4.8 mg monthly dose achieved placebo-adjusted weight loss of up to 12.3%, with no plateau observed at 32 weeks. If Phase 3 — spanning 10 planned studies — confirms the results, berobenatide could become the first monthly injectable GLP-1, a meaningful convenience improvement over current weekly regimens.
Read full story →FDA issues warning letters to telehealth companies for misleading compounded semaglutide and tirzepatide marketing
TLDR: The FDA issued warning letters to more than 25 telehealth companies that marketed compounded semaglutide and tirzepatide with claims implying FDA approval or equivalence to brand-name drugs like Ozempic and Wegovy. Companies allegedly told consumers their compounded products came from FDA-approved pharmacies or contained clinically studied ingredients — claims the FDA says create a misleading impression that the products are approved or proven safe. The action is part of an ongoing enforcement campaign targeting telehealth firms selling unapproved compounded GLP-1 drugs.
Read full story →Name recognition, not just efficacy, is driving early oral Wegovy uptake over rival GLP-1 pills, physician surveys show
TLDR: Monthly surveys of prescribing physicians by Spherix Global Insights find that familiarity with semaglutide — the active ingredient shared by injectable Ozempic and oral Wegovy — is the primary factor behind oral Wegovy outpacing Eli Lilly's oral GLP-1 competitor Foundayo in early uptake. Doctors reported greater comfort prescribing a molecule they had used for years in injection form. The finding suggests that in the emerging oral GLP-1 market, brand equity built on injectable experience may be as decisive as head-to-head efficacy data.
Read full story →Yesterday — Monday, June 22, 2026
4 articlesWegovy pill prescriptions surpass 3 million at ADA 2026, one of strongest US pharma launches on record
TLDR: Novo Nordisk announced that oral Wegovy (semaglutide tablets 25 mg) surpassed 3 million prescriptions in just over five months since its January 2026 launch — one of the strongest US pharmaceutical launches by volume on record — while presenting new clinical data at the American Diabetes Association 2026 Scientific Sessions. More than 80% of new Wegovy pill prescriptions are going to people who have never used a GLP-1 therapy before, suggesting the oral formulation is expanding access rather than simply converting patients from injections. Novo Nordisk also noted that eligible Medicare patients will be able to access Wegovy for a $50 monthly copay under the CMS GLP-1 Bridge beginning July 1.
Read full story →GLP-1 drugs linked to surprising drop in violent behavior in Rutgers study
TLDR: A Rutgers University study published in the journal Criminology found the link between impulsivity and violent behavior was about 62% weaker among current GLP-1 users compared to former users, and the alcohol-to-violence connection was about 52% weaker, based on a national survey of more than 7,500 US adults. Researchers say the findings suggest GLP-1 drugs may function like cognitive behavioral therapy — not eliminating impulsivity, but weakening the path from impulse to action — which could carry public safety implications as these medications become more widespread. The study is observational and cannot prove causation; the team is calling for longitudinal trials to test whether the effect is real and to identify underlying mechanisms.
Read full story →Semaglutide slowed biological aging by 9% in first placebo-controlled trial, UC San Diego finds
TLDR: A randomized, placebo-controlled trial from UC San Diego — published in Nature Communications — found that semaglutide slowed the pace of biological aging by 9% as measured by the DunedinPACE epigenetic clock, and reduced aging markers tied to inflammation, organ health, and all-cause mortality risk in adults with HIV, marking the first RCT evidence of a GLP-1 drug affecting cellular aging. Researchers believe the mechanism may involve reducing chronic inflammation and metabolic stress — processes that drive accelerated aging in people with HIV but are also central to obesity-related health decline in the broader population. Larger trials are needed to confirm how long these effects last and whether they extend to people without HIV, but the findings are prompting plans to pair GLP-1 therapy with lifestyle interventions in future studies.
Read full story →GLP-1 era calls for combined approach: medications, endoscopy, surgery, and precision medicine
TLDR: A commentary published in Gastroenterology by the American Gastroenterological Association updates the influential POWER obesity framework for the GLP-1 era, calling for a shift away from medication-only thinking toward combination care that pairs GLP-1 drugs with endoscopic procedures, bariatric surgery, and precision medicine tailored to each patient. The AGA argues that obesity should be treated as a chronic multi-system disease — with BMI no longer serving as the sole measure of treatment need — and that gastroenterologists are uniquely positioned to lead this integrated care given how many obesity-related conditions they already manage. Emerging evidence cited in the commentary suggests pairing GLP-1s with endoscopic sleeve gastroplasty may produce greater and longer-lasting weight loss than either approach alone.
Read full story →Wednesday — Wednesday, June 17, 2026
3 articlesMost People Who Stop GLP-1 Drugs Like Ozempic Eventually Return, ENDO 2026 Data Show
TLDR: New data presented at ENDO 2026 found that most patients who stop GLP-1 medications eventually restart therapy: 41.5% reinitiated within one year of stopping, and nearly 58% did so within two years. The findings reframe the conventional concern about long-term adherence, suggesting that discontinuation is often temporary rather than permanent for the majority of users. For clinicians and patients, this positions GLP-1 interruptions as a common, manageable phase of ongoing treatment rather than a failure.
Read full story →GLP-1 Drugs Linked to 50%-Plus Drop in Risk of Pancreatic, Colorectal, and Other Obesity-Related Cancers
TLDR: A study published June 16 found that GLP-1 receptor agonists are associated with substantially reduced risk of developing multiple obesity-related cancers including pancreatic and colorectal cancers in people without diabetes, with reductions exceeding 50% for some cancer types. The findings are distinct from the recent ASCO breast cancer data and strengthen the case that GLP-1 drugs may carry broad anti-cancer properties independent of weight loss. Researchers say the mechanism behind the reduction is not fully understood and warrants further investigation.
Read full story →Tirzepatide Bests Semaglutide in Large-Scale 12-Month Real-World Study, but Racial Disparities Emerge
TLDR: A PNAS Nexus study of more than 10,000 matched patients found tirzepatide users lost significantly more weight than semaglutide users over 12 months, with nearly twice as many achieving the high-responder threshold of 15% body weight lost. The study also flagged meaningful demographic gaps: women and white patients were significantly more likely to be high responders on either drug, while men and Black and Hispanic patients tended to see smaller benefits. The disparity data add an important public health dimension to the ongoing clinical comparison between these two leading GLP-1 medications.
Read full story →Tuesday — Tuesday, June 16, 2026
4 articlesTrump's Obesity Drug Plan Creates a Temporary Medicare Program That May Be Hard to End
TLDR: Starting July 1, Medicare will cover Wegovy, Zepbound, and Foundayo at a $50/month copay under an 18-month GLP-1 Bridge demonstration program — but STAT News analysis suggests the temporary structure may be politically difficult to wind down despite its December 2027 expiration date. CMS officials are hoping to transition to a permanent BALANCE model in 2028, though that launch is not guaranteed. Policy experts say the bridge program sets an expectation of coverage that Congress and CMS will face sustained pressure to maintain.
Read full story →Diabetes Patients on Semaglutide Had Fewer Fractures, Study Finds
TLDR: A retrospective analysis of 161 million U.S. patient records, presented at ENDO 2026 in Chicago, found that adults with type 2 diabetes on semaglutide had a 15% lower risk of bone fractures compared with those on other anti-obesity medications. The finding is notable because rapid weight loss from GLP-1s has previously raised concerns about bone density loss, but this real-world data suggests semaglutide may carry a protective bone effect. Stanford researchers called for prospective studies to confirm the result.
Read full story →Tirzepatide GLP-1 Medication May Be Most Effective for Weight Loss
TLDR: A meta-analysis of 15 phase 3 trials involving more than 14,000 non-diabetic patients found tirzepatide produced greater than 20% average body weight loss — outpacing semaglutide at roughly 15% and liraglutide at 8%. The dual GLP-1 and GIP receptor mechanism appears to drive the additional efficacy, with the 10–15 mg dose range producing the largest reductions. The findings are consistent with head-to-head trial data and are expected to influence prescribing decisions as oral GLP-1 options continue to enter the market.
Read full story →Popular Weight-Loss Drugs Like Ozempic Linked to Lower Breast Cancer Risk
TLDR: A Penn Medicine study of more than 111,000 women, presented at the 2026 ASCO Annual Meeting, found that those taking GLP-1 medications had a 30–47% lower likelihood of developing breast cancer compared to non-users. The large observational study adds to a growing body of evidence that GLP-1 drugs may reduce cancer risk through mechanisms beyond weight loss, though researchers caution the study does not definitively establish causation. If confirmed in prospective trials, the finding could meaningfully expand the clinical rationale for GLP-1 prescribing.
Read full story →Monday — Monday, June 15, 2026
3 articlesPeople taking GLP-1 weight loss drugs like Ozempic started moving less
TLDR: People with obesity who started GLP-1 drugs like Ozempic, Wegovy, and Zepbound saw meaningful declines in physical activity, with average daily steps falling from 5,047 to 4,487 and moderate-to-vigorous exercise dropping from 28 to 22 minutes per day, according to an NIH All of Us dataset analysis presented at ENDO 2026 in Chicago. The finding raises concern because GLP-1 medications also reduce lean muscle mass alongside fat, making exercise especially important — yet the drugs appear to suppress the drive to move. Clinicians are being encouraged to proactively pair structured exercise plans with GLP-1 prescriptions to counter the effect.
Read full story →Novo reports data breach, tells clinical trial patients to remain vigilant
TLDR: Novo Nordisk, maker of Ozempic and Wegovy, disclosed a cybersecurity breach in which unauthorized parties copied clinical trial data — including patient biomarkers, health indicators, and lifestyle factors — from its internal IT systems. While patient data was pseudonymized, healthcare professionals whose information was also exposed had names, contact details, and office locations taken; Novo has engaged external cybersecurity experts and notified relevant authorities. The breach underscores growing security risks for pharma companies holding sensitive clinical data as GLP-1 drug development accelerates.
Read full story →GLP-1 and SGLT2 Users Face Different Risk for Diabetic Foot Complication
TLDR: A large real-world analysis presented at the Endocrine Society annual meeting in Chicago found that GLP-1 receptor agonists were associated with significantly lower risks of major diabetic foot complications compared with SGLT2 inhibitors in adults with type 2 diabetes. The findings add nuance to ongoing head-to-head comparisons of these two major drug classes, which are increasingly prescribed to overlapping patient populations. GLP-1 drugs may offer meaningful protection against serious foot outcomes — a leading driver of diabetes-related hospitalizations and amputations — though results vary across study designs.
Read full story →Sunday — Sunday, June 14, 2026
3 articlesWant Obesity Drugs Covered by Insurance? Telehealth Companies Have a Big Say
TLDR: An NPR investigation reveals that employer-contracted telehealth companies like Vida Health and Virta Health are functioning as cost-control gatekeepers for GLP-1 prescriptions — in some cases steering patients toward unapproved medications or pulling them off Wegovy and Zepbound even after their own physicians had prescribed the drugs. Multiple patients reported significant harm from the practice, including weight regain after being removed from effective therapy. Obesity medicine specialists warn the model prioritizes cost reduction over evidence-based care, creating a growing conflict between employer interests and patient outcomes.
Read full story →GLP-1 Users Show Significant Drop in Physical Activity After Starting Medication, ENDO 2026 Study Finds
TLDR: A study presented at ENDO 2026 found that GLP-1 users experienced a meaningful decline in physical activity after starting treatment — average daily steps fell from 5,047 to 4,487 and moderate-to-vigorous activity dropped from 28 to 22 minutes per day, based on Fitbit data from 753 participants in the All of Us research program. The decline was sharpest among men and those with musculoskeletal pain. Researchers say the preliminary findings underscore the need for clinicians to actively promote exercise alongside GLP-1 therapy, since weight loss alone does not appear to increase physical movement.
Read full story →GLP-1 Receptor Agonists Linked to Lower Risk of Major Diabetic Foot Complications Than SGLT2 Inhibitors
TLDR: A large, real-world analysis presented at ENDO 2026 found that GLP-1 receptor agonists were associated with significantly lower risks of major diabetic foot complications — including amputations and serious lower-limb events — compared with SGLT2 inhibitors in adults with type 2 diabetes. The findings add to an evolving evidence base comparing these two drug classes on lower-extremity outcomes and suggest GLP-1s may be preferable for patients at elevated risk of diabetic foot disease. Researchers noted the results should inform individualized treatment decisions, particularly in patients with existing neuropathy or peripheral artery disease.
Read full story →Saturday — Saturday, June 13, 2026
3 articlesNovo Nordisk discloses data breach exposing clinical trial patient data
TLDR: Novo Nordisk reported a cybersecurity breach in which pseudonymized patient data from some clinical trials was copied externally without authorization, exposing health metrics, biomarkers, lifestyle factors, and — for healthcare professionals — names and contact details. The company says manufacturing and supply chains are unaffected, and it is working with external cybersecurity experts while notifying relevant authorities. Patients and providers in affected trials have been advised to remain vigilant as the investigation continues.
Read full story →FDA compounded GLP-1 ban heads to final stretch: public comment closes June 29
TLDR: The FDA's April 30 proposal to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list is entering its final public comment window, closing June 29, 2026. If finalized — expected late summer — large-scale 503B compounders would be prohibited from bulk-producing these drugs in any circumstances, though 503A pharmacies filling individual prescriptions would remain permitted. The FDA cited resolution of the national supply shortage and more than 455 adverse event reports linked to compounded semaglutide as justification.
Read full story →An obesity drug deep-dive, and peptides move mainstream
TLDR: STAT News surveys the crowded obesity drug pipeline coming out of the American Diabetes Association meeting, noting that no next-generation candidate has yet emerged as a clear challenger to semaglutide and tirzepatide. The piece also tracks how peptides like BPC-157 have traveled from underground bodybuilding forums to mainstream consumer interest — a trend regulators are beginning to scrutinize. A record-breaking biotech IPO rounds out the week's market news.
Read full story →Friday — Friday, June 12, 2026
4 articlesMedicare GLP-1 Bridge Program Launches July 1 at $50/Month for Beneficiaries
TLDR: CMS is launching a Medicare GLP-1 Bridge Program on July 1, 2026, capping out-of-pocket costs at $50 per month for eligible Medicare beneficiaries seeking GLP-1 medications for obesity. The program runs as a standalone demonstration through December 2027, separate from Part D coverage, so plans do not need to opt in and beneficiaries do not bear financial risk. For the roughly 67 million Medicare enrollees, this represents the most direct federal access expansion for GLP-1 weight-loss drugs to date.
Read full story →More Employers Are Dropping GLP-1 Weight-Loss Coverage as Costs Surge
TLDR: A growing wave of large employers is cutting GLP-1 coverage for weight management as usage and costs escalate — major insurers like HCA Healthcare and multiple Blue Cross Blue Shield plans have already dropped benefits. A Business Group on Health survey found roughly 1 in 10 companies currently covering GLP-1s for obesity plan to stop by 2027, driven by prescription drug spending that surged as much as 90% at some organizations. Coverage for diabetes-indicated GLP-1 prescriptions is generally being maintained; the cuts are targeted specifically at the weight-loss designation.
Read full story →Semaglutide and Tirzepatide Show Hair Loss Signals in 10-Year FDA Adverse Event Review
TLDR: A 10-year analysis of the FDA Adverse Event Reporting System (FAERS) found statistically significant alopecia signals for semaglutide (reporting odds ratio 2.46) and tirzepatide (ROR 1.73) — the only two GLP-1 drugs to generate such signals in the review. Proposed mechanisms include the drugs extended half-lives and rapid calorie-restriction-induced telogen effluvium. Researchers called for ongoing pharmacovigilance as prescriptions for both drugs continue to scale.
Read full story →AstraZeneca Advances Oral GLP-1 Elecoglipron to Broad Phase 3 Program After Strong Phase 2 Results
TLDR: AstraZeneca will launch an extensive Phase 3 program for elecoglipron, its oral GLP-1 pill, after Phase 2b data presented at ADA 2026 showed 10.5-11.8% weight loss at 36 weeks versus 0.3% for placebo. The pivotal EMBOLD obesity trials and ELUMINATE diabetes studies are slated to begin in the second half of 2026, putting AstraZeneca in direct competition with Novo Nordisks oral Wegovy and Lillys Foundayo. A successful Phase 3 would add a third major oral GLP-1 to a rapidly crowding market.
Read full story →Thursday — Thursday, June 11, 2026
3 articlesFDA Moves to Permanently Bar Bulk Compounding of Semaglutide, Tirzepatide, and Liraglutide as June 29 Comment Deadline Nears
TLDR: The FDA is proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, concluding there is no clinical need for outsourcing facilities to compound these drugs in bulk now that brand-name supplies have stabilized; the public comment period closes June 29, 2026. If finalized, the rule would foreclose large-scale compounded GLP-1s even if a future shortage were declared. For patients who turned to lower-cost compounded versions, it signals that those options could narrow substantially in the months ahead.
Read full story →Telehealth GLP-1 Boom Raises Safety and Oversight Concerns as Medication Errors Climb
TLDR: A KFF Health News investigation, co-published with NBC News, examines how the rapid growth of online weight-loss companies has made GLP-1 prescriptions easy to obtain while raising concerns about inadequate patient screening, dosing errors, and limited follow-up care. Reported medication errors involving popular weight-loss drugs rose from roughly 2,000 in 2020 to more than 25,000 in 2025, and poison-control calls tied to injectable versions have surged. The reporting underscores why a proper medical evaluation and ongoing monitoring matter when starting a GLP-1, no matter where the prescription comes from.
Read full story →Medicare GLP-1 Bridge Launches July 1 as the Only Coverage Path After BALANCE Model Is Shelved
TLDR: With CMS shelving its broader BALANCE model indefinitely in April, the Medicare GLP-1 Bridge will go live July 1 as the only pathway for Medicare beneficiaries to access obesity medications, covering Wegovy, Zepbound, or Foundayo for a flat $50 monthly copay. The demonstration runs outside Part D, is processed by Humana, and was quietly extended through December 2027, with prior authorization tied to BMI-based eligibility tiers and full CMS guidance expected in June. Because the program lacks statutory backing, beneficiaries could face an abrupt coverage cliff when it expires unless Congress acts.
Read full story →Wednesday — Wednesday, June 10, 2026
5 articlesLarge Study Links GLP-1s to Lower Risk of Multiple Cancers
TLDR: A large propensity-matched cohort study presented at ADA 2026 found that patients taking GLP-1 receptor agonists for obesity had a 41% lower risk of obesity-related cancers than those managing weight through diet or exercise alone. The finding adds to mounting evidence that GLP-1s may carry benefits beyond weight loss and blood-sugar control. Researchers cautioned that observational data cannot prove causation, and randomized trials would be needed to confirm a protective effect.
Read full story →Monthly GLP-1 for Obesity Promising as More Manageable Alternative
TLDR: Researchers at ADA 2026 reported that an investigational ultra-long-acting GLP-1 agonist produced significant weight loss in people with overweight or obesity, with reductions holding up even after participants switched to once-monthly dosing. A monthly injection could ease the adherence burden of current once-weekly GLP-1s for some patients. The drug remains in development and is not yet available.
Read full story →ADA 2026: Lilly's Dominance, Pfizer's 'Foundational' Drug and Roche's 'Me-Too' Option
TLDR: In a wrap-up of ADA 2026, BioPharma Dive reported that Eli Lilly's triple-hormone agonist retatrutide set a new weight-loss benchmark while doubts lingered around competing obesity drugs from Pfizer, Roche and others. The analysis underscores how far ahead Lilly and Novo Nordisk remain as a crowded field of next-generation contenders jockeys for position. Which challengers reach the market, and how they are priced, will shape patients' options over the next few years.
Read full story →ADA: Lilly Posts Oral Semaglutide-Topping Data as Foundayo Speeds Toward 2nd Potential Nod in Diabetes
TLDR: At ADA 2026, Eli Lilly presented data it says show its oral pill orforglipron (branded Foundayo) outperforming oral semaglutide, as the company pushes for a second approval in type 2 diabetes on top of its existing obesity indication. A convenient daily pill that rivals injectable results could broaden access for patients who avoid needles. A regulatory decision on the diabetes indication is still pending.
Read full story →ADA: Amgen Highlights Repatha Perks, GLP-1 Pitfalls in Push to Boost Cardiometabolic Pedigree
TLDR: Amgen used ADA 2026 to spotlight its cholesterol drug Repatha and to flag tolerability and durability concerns with GLP-1s as it works to build a cardiometabolic franchise. The messaging reflects intensifying competition as drugmakers position GLP-1s and other therapies for heart and metabolic risk reduction. For patients, the broader pipeline could eventually mean more combination and alternative options beyond today's GLP-1s.
Read full story →Tuesday — Tuesday, June 9, 2026
4 articlesAstraZeneca's GLP-1 pill shows promise in obesity, diabetes trials
TLDR: AstraZeneca reported mid-stage trial results for its experimental oral GLP-1, showing meaningful weight loss and blood-sugar improvements in people with obesity and type 2 diabetes. The data mark another serious entrant in the race for a convenient daily pill, though analysts say it is still too early to know how it compares with rivals from Lilly and Novo Nordisk. Later-stage trials will determine whether it can carve out a place in an increasingly crowded oral market.
Read full story →Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
TLDR: Phase III data presented at ADA 2026 showed Boehringer Ingelheim's survodutide, a GLP-1/glucagon dual agonist, produced significant weight loss and notable reductions in liver fat in people with obesity and fatty liver disease (MASLD). The benefits came alongside tolerability concerns, as gastrointestinal side effects led some patients to discontinue. The mixed profile raises questions about where survodutide will fit as a wave of newer obesity drugs reaches the market.
Read full story →ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
TLDR: Novo Nordisk said its oral version of Wegovy, the first GLP-1 pill for obesity, has surpassed 3 million prescriptions since launching earlier this year. The milestone signals strong early demand for a needle-free option and helps Novo defend market share against Lilly's oral contender. Notably, the pill appears to be reaching patients new to GLP-1 therapy, suggesting it is expanding the market rather than simply converting existing injection users.
Read full story →GLP-1, Amylin Analog Combo Cuts Blood Sugar, Weight in Diabetes Trials
TLDR: A once-weekly fixed-dose combination of the amylin analog cagrilintide and semaglutide lowered both blood sugar and body weight across several diabetes patient groups in trials reported at ADA 2026. The combination, Novo Nordisk's CagriSema program, is being positioned as a more potent option than semaglutide alone. If the results hold in larger studies, it could give patients another high-efficacy choice as competition in the field intensifies.
Read full story →Monday — Monday, June 8, 2026
4 articlesGLP-1 Drugs Linked to 30% Lower Breast Cancer Risk in Large Cohort Study
TLDR: A Penn Medicine cohort study of more than 111,000 women, presented at ASCO 2026 and published in JCO Oncology Practice, found that GLP-1 drug users were roughly 30% less likely to develop breast cancer after adjusting for age, BMI, and other risk factors. The finding adds to growing evidence that GLP-1 medications may carry cancer-preventive benefits beyond weight loss. The study was observational, so causality is not established, and researchers are calling for larger prospective trials.
Read full story →Medicare GLP-1 Bridge Program Launches July 1 With $50 Monthly Copay
TLDR: Starting July 1, 2026, eligible Medicare Part D beneficiaries can access Wegovy, Zepbound, or Foundayo for a flat $50 monthly copay — no deductible applies — under the new Medicare GLP-1 Bridge program. The program targets seniors with BMI 35 or higher, or BMI 27-30 with qualifying conditions like pre-diabetes or prior heart attack, representing the broadest Medicare expansion of GLP-1 weight-loss coverage to date. The bridge runs through December 2027 while CMS gathers utilization data ahead of the wider BALANCE model launch in Medicare Part D.
Read full story →Retatrutide Hits Major A1c and Weight Loss Benchmarks in Phase 3 TRANSCEND-T2D-1 Trial
TLDR: Eli Lilly presented full results from the phase 3 TRANSCEND-T2D-1 trial at ADA 2026 showing retatrutide — its triple GIP/GLP-1/glucagon receptor agonist — achieved A1c below 7% in 90% of participants, with those on the 12 mg dose losing an average of 36.6 lbs over 40 weeks. The results position retatrutide as a potential best-in-class option for type 2 diabetes, pairing robust glycemic control with near-bariatric-level weight loss in a once-weekly injection. The drug is not yet FDA-approved; Lilly is expected to file a diabetes indication following completion of the broader phase 3 program.
Read full story →Pfizer Monthly Obesity Drug Berobenatide Shows 10-12% Weight Loss in Phase 2b Trial
TLDR: Pfizer presented phase 2b data at ADA 2026 showing its once-monthly injectable berobenatide delivered 10-12% placebo-adjusted weight loss at 28 weeks with a side-effect profile comparable to weekly GLP-1 injections like Wegovy. A monthly dosing schedule could be a meaningful competitive edge in the crowded obesity drug market, lowering the injection burden for patients. Pfizer is advancing 10 late-stage programs for berobenatide in 2026, though pivotal phase 3 results will be required before any FDA submission.
Read full story →Sunday — Sunday, June 7, 2026
3 articlesLilly Shares Safety and Tolerability Data on Triple-Agonist Retatrutide at ADA 2026
TLDR: Eli Lilly presented new safety and tolerability data on retatrutide, its next-generation obesity drug targeting GIP, GLP-1, and glucagon receptors, at the American Diabetes Association meeting in New Orleans on Saturday. Tolerability has been the open question for triple agonists, so this readout shapes how the most potent class of weight-loss candidates moves toward market. Full late-stage efficacy results remain the next milestone to watch.
Read full story →Detailed Mid-Stage Data Back Monthly Dosing for Pfizer Obesity Drug Acquired From Metsera
TLDR: Detailed results from a midstage study presented at ADA 2026 offered further evidence that the obesity drug Pfizer acquired from biotech Metsera could be dosed monthly. Every injectable GLP-1 on the market today is dosed weekly, so a once-a-month option could meaningfully improve adherence and convenience for patients. Larger trials will need to confirm the dosing schedule before it reaches patients.
Read full story →ADA 2026: First-Ever Obesity Standards of Care Land as Payers Weigh GLP-1 Pipeline Data
TLDR: The American Diabetes Association is releasing its inaugural Standards of Care in Overweight and Obesity at its 2026 Scientific Sessions, guidance that health plans and PBMs are expected to use to anchor coverage criteria for weight-loss drugs. The managed care backdrop is stark: one recent analysis found GLP-1 adherence falls from 65% at 120 days to just 34% at one year, with out-of-pocket cost a key driver of discontinuation. Coverage decisions on next-generation agents over the next 12-24 months will lean heavily on the evidence presented this week.
Read full story →Saturday — Saturday, June 6, 2026
3 articlesGLP-1 Use Linked to Lower Long-Term Risk of Knee Replacement in Osteoarthritis Patients
TLDR: A large TriNetX real-world cohort study published in Regional Anesthesia & Pain Medicine found GLP-1 receptor agonist use was associated with a significantly lower long-term risk of total knee replacement among patients with knee osteoarthritis. The benefit was strongest with newer agents like semaglutide and tirzepatide used for at least three years, reaching a 4.71-percentage-point absolute reduction in surgery risk at eight years. Researchers say the effect may reflect disease-modifying activity beyond weight loss alone, though prospective trials are still needed to confirm causality.
Read full story →Some High-Risk Patients Progress to Diabetes Despite Sustained Weight Loss, 9-Year Study Finds
TLDR: New nine-year data from the Tubingen Lifestyle Intervention Program, highlighted at ADA 2026 and published in Diabetes, found that one high-risk subgroup of people with prediabetes progressed to type 2 diabetes despite sustained 8% weight loss, with 41% converting versus 0% in lower-risk groups losing comparable weight. The pattern was tied to fatty liver and declining insulin secretion, suggesting weight loss alone is not a reliable shield against diabetes for everyone. The findings strengthen the case for matching prevention strategies, including GLP-1 therapy, to a patient's specific metabolic profile rather than the scale.
Read full story →GLP-1 Medication Errors Surge as Telehealth Demand Outpaces Oversight
TLDR: A KFF Health News investigation, co-reported with NBC News, documents a sharp rise in GLP-1 medication errors as telehealth companies make weight-loss drugs easier to obtain online, with FDA adverse-event reports climbing from roughly 2,000 in 2020 to more than 25,000 in 2025. Reporters detailed cases of patients hospitalized after telehealth providers prescribed doses far above standard starting amounts, often with minimal follow-up care. The piece highlights growing scrutiny of asynchronous prescribing and compounded semaglutide as regulators and drugmakers escalate enforcement.
Read full story →Friday — Friday, June 5, 2026
4 articlesAccumulating Evidence Lifts GLP-1s to Clinical Trial for Breast Cancer Prevention
TLDR: A large cohort study of more than 30,000 women presented at ASCO 2026 found that those with prior GLP-1 use had approximately 30% lower breast cancer incidence, with the benefit holding across age, race, BMI, and diabetes status. The finding matters because it suggests GLP-1 drugs may offer protective effects beyond weight loss, though whether the mechanism is metabolic, direct receptor activity in breast tissue, or reduced inflammation remains unclear. Researchers are now calling for prospective clinical trials to determine whether the association is causal before GLP-1s can be formally considered for cancer prevention.
Read full story →Medicare GLP-1 Bridge to Launch July 1 With $50 Monthly Copay for Seniors
TLDR: Starting July 1, 2026, CMS will offer eligible Medicare Part D enrollees access to Wegovy, Zepbound, and Foundayo at a flat $50 per month through the Medicare GLP-1 Bridge demonstration, which runs through December 2027. The program is a major access shift for seniors who have largely been priced out of GLP-1 drugs costing $1,000 or more monthly without coverage. Beneficiaries should talk to their doctor now about eligibility, as prior authorization processes are still being finalized ahead of the July 1 launch.
Read full story →FDA Proposes Removing Semaglutide and Tirzepatide From 503B Compounding Bulks List
TLDR: The FDA has proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, a move that would close off large-scale compounding of these GLP-1 drugs by outsourcing facilities, with a public comment window closing June 29, 2026. If finalized, this effectively ends the legal pathway for 503B compounders to produce these medications at scale, directly affecting telehealth companies that have relied on outsourcing facilities for affordable compounded GLP-1 products. Patients currently receiving compounded GLP-1s through telehealth should speak with their providers about transitioning to branded alternatives before potential enforcement actions follow.
Read full story →Lilly Acquires GLP-2 Obesity Drug in Active Dealmaking Week
TLDR: Eli Lilly acquired rights to a next-generation GLP-2 obesity drug from Hanmi Pharmaceutical, expanding its portfolio beyond existing GLP-1 and GIP therapies like Zepbound in a busy dealmaking week. The move signals Lilly is investing in post-GLP-1 obesity mechanisms even as the current market matures, with competitors also pursuing new molecular targets. Any GLP-2 product would be years from approval, but the deal reflects deep industry conviction that the obesity drug market has substantial room to grow beyond today's options.
Read full story →Thursday — Thursday, June 4, 2026
3 articlesNovo Nordisk Brings CagriSema and Next-Gen Zenagamtide Data to ADA 2026
TLDR: Ahead of the ADA Scientific Sessions opening June 5 in New Orleans, Novo Nordisk detailed a slate of presentations spanning its cardiometabolic pipeline. Highlights include new analyses of CagriSema (the cagrilintide-semaglutide combination) and first mid-stage data for zenagamtide, an investigational injectable GLP-1/amylin candidate, alongside readouts for IcoSema and efruxifermin. The push signals Novo's effort to defend its obesity franchise against Eli Lilly's retatrutide as the field's most closely watched meeting begins.
Read full story →Innovent to Present Mazdutide and Next-Generation Obesity Pipeline at ADA 2026
TLDR: Innovent Biologics will showcase multiple clinical and preclinical datasets for mazdutide, its GLP-1/glucagon dual agonist already approved in China, plus earlier-stage metabolic candidates at the 2026 ADA Scientific Sessions. The presentations underscore how Chinese developers are emerging as serious challengers in the global obesity drug race rather than regional-only players.
Read full story →Researchers Map the Case for Repurposing GLP-1 Drugs in Neurologic Disease
TLDR: A new clinical review surveys the growing evidence for GLP-1 receptor agonists beyond metabolism, examining trials and mechanistic data in Alzheimer's disease, Parkinson's disease, and stroke recovery. The authors describe promising but still-mixed results, noting that anti-inflammatory and neuroprotective effects may underpin benefits while cautioning that larger confirmatory trials are needed before the drugs enter neurology practice.
Read full story →Tuesday — Tuesday, June 2, 2026
4 articlesADA 2026: GLP-1 Giants and Upstarts Set for Obesity Showdown in New Orleans
TLDR: The American Diabetes Association's Scientific Sessions (June 5-8, New Orleans) will feature a packed obesity lineup. Eli Lilly is presenting full Phase 3 TRIUMPH-1 data on triple-agonist retatrutide (28.3% weight loss), Novo Nordisk brings CagriSema, and Boehringer/Zealand show detailed SYNCHRONIZE-1 results for survodutide. Smaller players including Viking Therapeutics (VK2735) and Structure Therapeutics (aleniglipron) will also present next-generation candidates.
Read full story →AstraZeneca's Once-Daily Oral GLP-1 Elecoglipron Hits Phase 2 Endpoints, Heads to Phase 3
TLDR: AstraZeneca announced that its in-licensed oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004) met primary endpoints in two Phase 2 trials: VISTA in obesity/overweight (310 participants, 36 weeks) and SOLSTICE in type 2 diabetes (406 participants, including a semaglutide comparator). The once-daily pill, taken without food restrictions, will advance to Phase 3, with full data due at ADA 2026.
Read full story →Genentech to Unveil Late-Breaking Enicepatide and Petrelintide Obesity Data at ADA 2026
TLDR: Genentech (Roche Group) will present late-breaking Phase 2 data at ADA 2026 for enicepatide (CT-388), a biased dual GLP-1/GIP receptor agonist, and petrelintide, a long-acting amylin analog from its Zealand Pharma partnership. Both candidates are moving into Phase 3, and the company plans to start a Phase 2 fixed-dose combination trial of the two drugs around mid-2026.
Read full story →Large U.S. Study Finds No Long-Term Thyroid Cancer Risk From GLP-1 Drugs
TLDR: A target-trial-emulation analysis of more than 351,000 adults with type 2 diabetes, published in JAMA Otolaryngology-Head & Neck Surgery, found no statistically significant increase in overall thyroid cancer risk among new GLP-1 users. A transient spike in diagnoses during the first year disappeared afterward, which the authors attribute to detection bias from increased thyroid screening rather than the drugs causing cancer.
Read full story →Monday — Monday, June 1, 2026
4 articlesFDA Proposes to Permanently Ban Large-Scale Compounding of Semaglutide and Tirzepatide
TLDR: The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list, which would permanently shut down large-scale compounding of GLP-1 medications. The agency cited over 455 adverse events linked to compounded semaglutide and 320+ linked to compounded tirzepatide. A public comment period is open through June 29, 2026.
Read full story →Medicare to Offer Wegovy and Zepbound for $50/Month Starting July 2026
TLDR: CMS announced a Medicare GLP-1 Bridge program launching July 1, 2026, allowing eligible Part D beneficiaries to access Wegovy, Foundayo, and Zepbound KwikPen for a $50 monthly copay through December 2027. Eligibility requires a BMI of 35 or higher, or 27 or higher with qualifying conditions.
Read full story →Wegovy Linked to Risk of Rare Eye Stroke Five Times Higher Than Ozempic, Study Finds
TLDR: An analysis of more than 30 million FDA adverse event reports found Wegovy is associated with a significantly elevated risk of ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The risk signal was nearly five times stronger for Wegovy than for Ozempic despite both containing semaglutide; tirzepatide-based drugs did not show the same signal.
Read full story →CMS Launches BALANCE Model to Negotiate Lower GLP-1 Prices for Medicaid and Medicare
TLDR: CMS launched the voluntary BALANCE Model, allowing it to negotiate GLP-1 drug prices directly with manufacturers on behalf of state Medicaid agencies and Medicare Part D plans. The Medicaid rollout began in May 2026, with Medicare Part D participation opening in January 2027.
Read full story →Sunday — Sunday, May 31, 2026
3 articlesAn Experimental GLP-1 Pushes the Limits of Weight Loss — and Raises New Questions
TLDR: Eli Lilly's retatrutide — a triple-receptor GLP-1 drug showing 28% average weight loss in trials — is prompting doctors to ask how much weight loss is too much, too fast. Clinicians warn of risks including 25-40% lean mass loss, elevated gallstone risk (37% higher relative risk vs. placebo), and bone density reduction with rapid loss.
Read full story →As Next-Gen GLP-1 Drugs Grow More Powerful, Experts Urge Caution Over Muscle and Bone Loss
TLDR: Scientific American examines the body composition risks accompanying the latest generation of high-potency GLP-1 drugs. Data from clinical trials show GLP-1 users lose 25-40% of their weight as lean mass, and rapid fat loss accelerates gallstone formation; obesity specialists are calling for better protein and resistance-training guidance alongside prescriptions.
Read full story →GLP-1 Drugs Easy to Obtain Online — and Overdoses Are Surging, KFF Investigation Finds
TLDR: A major KFF Health News investigation finds that telehealth companies dispensing GLP-1 drugs online have fueled a nearly 1,500% rise in poison control calls since 2019, with some patients receiving doses nine times the recommended starting amount. FDA adverse event reports for GLP-1 medication errors jumped from roughly 2,000 in 2020 to over 25,000 in 2025.
Read full story →Saturday — Saturday, May 30, 2026
3 articlesASCO 2026: GLP-1 Drugs Linked to 38-50% Reduction in Cancer Spread Across Four Tumor Types
TLDR: Cleveland Clinic researchers presented real-world data at ASCO 2026 showing GLP-1 receptor agonists were associated with 38-50% reductions in metastatic progression for lung, breast, colorectal, and hepatocellular cancers compared to DPP-4 inhibitors in a propensity-matched cohort of 12,112 patients. High tumor GLP-1 receptor expression was independently linked to a 33% lower risk of death — and a 45% lower risk in breast cancer specifically. Researchers called the findings compelling enough to warrant prospective randomized trials.
Read full story →ASCO 2026: GLP-1 Medications Cut Obesity-Related Cancer Risk by 7% in 170,000-Patient Study
TLDR: A large NYU-led observational study of 170,000 people with diabetes and obesity found that GLP-1 receptor agonists reduced overall obesity-related cancer risk by 7% and all-cause mortality by 8% compared to DPP-4 inhibitors. The protective effect was especially strong for colorectal cancer — 16% fewer colon cancers and 28% fewer rectal cancers in the GLP-1 group. Women on GLP-1s saw a 20% lower risk of all-cause death compared to women on DPP-4 inhibitors.
Read full story →AI Analysis of 400,000 Reddit Posts Uncovers Hidden GLP-1 Side Effects Including Menstrual Changes and Fatigue
TLDR: University of Pennsylvania researchers used large language models to analyze over 400,000 Reddit posts from nearly 70,000 GLP-1 users and surfaced symptoms underrepresented in official drug labeling, including menstrual irregularities (reported by nearly 4% of female users), chills, hot flashes, and fatigue ranking as the second most common complaint. Published in Nature Health, the study argues AI-powered social media surveillance could serve as a faster early-warning system for emerging drug safety signals.
Read full story →Friday — Friday, May 29, 2026
3 articlesLilly's Retatrutide Achieves 28% Average Weight Loss in Phase 3 Trial, Setting New Benchmark
TLDR: Eli Lilly's triple-agonist drug retatrutide hit its primary goal in the Phase 3 TRIUMPH-1 trial, with participants losing an average of 28% of body weight over 80 weeks — the highest ever recorded in a medication trial to date. The drug simultaneously activates receptors for GIP, GLP-1, and glucagon, yielding greater efficacy than Lilly's own Zepbound and rival Wegovy. Physicians caution that ultra-potency may bring proportionally greater risks including muscle loss.
Read full story →ECO 2026: Magnitude of GLP-1 Weight Loss Strongly Predicts Reduction in Obesity-Related Disease Risk
TLDR: Research presented at the European Congress on Obesity found that patients who lost the most weight on GLP-1 medications saw the greatest reductions in risk for obesity-related conditions, including type 2 diabetes, cardiovascular disease, and sleep apnea. The analysis reinforces a clear dose-response relationship between the magnitude of weight loss and long-term health benefit. Researchers say the findings support more aggressive treatment targets for patients who tolerate higher doses.
Read full story →NIH: Oral Small-Molecule GLP-1 Drugs Suppress Pleasure-Driven Eating via Deep Brain Reward Circuits
TLDR: A NIH-funded study found that small-molecule oral GLP-1 drugs like orforglipron reach deep reward circuits in the brain — including the nucleus accumbens — and suppress hedonic, or pleasure-driven, eating in mouse models. Unlike peptide GLP-1s, these orally absorbed molecules cross the blood-brain barrier more readily, which may help explain their appetite suppression. The findings could guide the design of next-generation treatments that more precisely target non-homeostatic hunger.
Read full story →Thursday — Thursday, May 28, 2026
5 articlesWegovy Linked to Rare "Eye Stroke" That Can Cause Sudden Blindness
TLDR: A BMJ study analyzing over 30 million FDA adverse event reports found Wegovy carries the strongest association with ischemic optic neuropathy (ION), a rare condition that can cause sudden vision loss. The statistical signal was nearly 75 times higher than expected for Wegovy and 5 times stronger than for Ozempic, despite both containing semaglutide. Researchers are calling for urgent follow-up studies to guide prescribing and regulatory policy.
Read full story →NIH Scientists Discover Why GLP-1 Weight Loss Eventually Plateaus
TLDR: NIH researchers found that semaglutide reduces appetite through cAMP signaling in hindbrain neurons, but some neurons lose responsiveness over time by internalizing GLP-1 receptors. Blocking the PDE4 enzyme with roflumilast extended the drug effects in lab tests, offering a potential path to overcoming the weight-loss plateau many patients experience. The findings, published in Nature Metabolism, may guide development of more effective future GLP-1 treatments.
Read full story →Medicare to Offer GLP-1 Drugs for $50 Per Month Starting July 2026
TLDR: CMS announced eligible Medicare Part D beneficiaries will gain access to Wegovy, Zepbound, and Foundayo for $50 per month beginning July 1, 2026 through December 2027 under the Medicare GLP-1 Bridge program. Eligibility requires a BMI of 35 or higher, or 27 or higher with qualifying clinical conditions. Notably, the $50 copay will not count toward the Part D deductible or the annual out-of-pocket cap.
Read full story →FDA Proposes Permanently Banning Bulk Compounding of GLP-1 Drugs
TLDR: The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List on April 30, finding no clinical need for outsourcing facilities to compound these drugs when FDA-approved versions are available. Public comments are open through June 2026 before a final ruling. The FDA previously received over 455 adverse event reports linked to compounded semaglutide and 320 tied to compounded tirzepatide, many involving dosing errors.
Read full story →Oral GLP-1 Pill Helps Patients Maintain Weight Loss After Stopping Injectables
TLDR: The ATTAIN-MAINTAIN Phase 3b trial, published in Nature Medicine, found that switching from injectable GLP-1s to once-daily oral orforglipron preserved 75-80% of weight loss and cardiometabolic improvements including reduced blood pressure and improved cholesterol. In a head-to-head comparison, tirzepatide users lost about 20% of body weight versus 14% for semaglutide users. The results suggest oral GLP-1s could serve as an effective long-term maintenance therapy.
Read full story →Wednesday — Wednesday, May 27, 2026
4 articlesScientists Discover Why Ozempic and Wegovy Weight Loss Eventually Plateaus
TLDR: NIH researchers found that semaglutide triggers varying cAMP responses inside appetite-regulating brain cells, explaining why GLP-1 drugs work differently for each person and why effects plateau over time. Scientists also identified roflumilast as a potential way to extend drug effectiveness by preventing cAMP breakdown. The findings, published in Nature Metabolism, may guide development of longer-lasting GLP-1 treatments.
Read full story →Wegovy Linked to Rare Eye Stroke That Can Cause Sudden Blindness
TLDR: A new analysis of over 30 million FDA adverse event reports found Wegovy carries the strongest association with ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The risk signal was nearly five times stronger for Wegovy than Ozempic despite both containing semaglutide, with men showing the highest signal. Researchers published in the British Journal of Ophthalmology are calling for urgent prospective studies.
Read full story →FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List
TLDR: The FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these GLP-1 drugs. The move would effectively end large-scale compounding of these medications by outsourcing facilities. Public comments are open through June 29, 2026.
Read full story →Oral GLP-1 Pill Helps Patients Maintain 75-80% of Injectable Weight Loss
TLDR: The ATTAIN-MAINTAIN phase 3b trial found that switching from injectable GLP-1s to the once-daily oral pill orforglipron helped patients maintain 75-80% of their weight loss along with cardiometabolic benefits. Published in Nature Medicine on May 12, the Weill Cornell-led trial suggests orforglipron could be a convenient injectable-free option for long-term weight maintenance. The drug is expected to reach pharmacies in Q4 2026.
Read full story →Tuesday — Tuesday, May 26, 2026
4 articlesEli Lilly Retatrutide Matches Bariatric Surgery With 30% Weight Loss in Phase 3 Trial
TLDR: Eli Lilly's triple agonist retatrutide achieved 30.3% average weight loss at 104 weeks in the Phase 3 TRIUMPH-1 trial, matching bariatric surgery outcomes for the first time in a drug trial. About 45% of participants lost 30% or more of body weight. Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors, making it the most potent weight-loss drug to reach Phase 3 data.
Read full story →Scientists Discover Why GLP-1 Weight Loss Eventually Plateaus
TLDR: New NIH-funded research reveals that semaglutide triggers different responses inside appetite-controlling brain cells, explaining why the drug's effects vary between patients and why weight loss plateaus over time. Researchers also identified a potential pathway to extend GLP-1 effectiveness beyond the plateau, which could lead to next-generation treatment strategies.
Read full story →GLP-1 Drugs Linked to 44% Lower Depression Risk and 38% Fewer Anxiety Disorders
TLDR: A large-scale study tracking nearly 100,000 people over more than a decade found that semaglutide use was associated with a 44% lower risk of depression and 38% fewer anxiety disorder diagnoses. The findings add to growing evidence that GLP-1 medications carry significant mental health benefits beyond weight loss and metabolic improvements.
Read full story →Medi-Cal Will No Longer Cover GLP-1 Medications for Weight Loss
TLDR: California's Medi-Cal program announced it will end coverage of GLP-1 medications prescribed for weight loss, a significant reversal that will affect millions of low-income patients who gained access under recent coverage expansions. The decision reflects mounting pressure on state Medicaid programs to contain the high per-patient costs of obesity drug regimens.
Read full story →Monday — Monday, May 25, 2026
4 articlesOral GLP-1 Pill Helps Patients Maintain Weight Loss After Stopping Injectables
TLDR: The ATTAIN-MAINTAIN trial, published May 12 in Nature Medicine, found that switching from injectable GLP-1s to once-daily orforglipron helped patients preserve 75-80% of their weight loss. The phase 3b study of 376 participants, sponsored by Eli Lilly, suggests the oral pill could serve as a practical long-term maintenance option for patients who want to move away from injections.
Read full story →Wegovy Linked to Rare Eye Stroke Risk Nearly Five Times Higher Than Ozempic, Study Finds
TLDR: A peer-reviewed analysis of 30.6 million FDA adverse event reports found Wegovy carries a risk signal for ischemic optic neuropathy (ION) nearly five times stronger than Ozempic, despite both containing semaglutide. ION can cause sudden partial or complete vision loss, and the signal was especially pronounced in men. Researchers are calling for urgent prospective studies to evaluate the dose-dependent safety concern.
Read full story →FDA Proposes Permanent End to Mass Compounding of Semaglutide and Tirzepatide
TLDR: The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would end large-scale outsourcing facility compounding of these drugs. The public comment period closes June 29, 2026. The action follows the agency's earlier determination that shortage conditions for brand-name GLP-1 medications have resolved.
Read full story →Bigger Weight Loss on GLP-1s Tied to Dramatically Better Health Outcomes, ECO 2026 Data Show
TLDR: Research presented at the European Congress on Obesity found that GLP-1 patients who lost more weight saw substantially greater reductions in cardiovascular risk factors and obesity-related complications. Patients who regained weight after starting treatment faced worse health outcomes, reinforcing the importance of continued medication adherence and addressing the long-term treatment gap.
Read full story →Sunday — Sunday, May 24, 2026
4 articlesWegovy Linked to Rare Eye Stroke Risk Five Times Higher Than Ozempic, Study Finds
TLDR: An analysis of over 30 million FDA adverse-event reports found that Wegovy carries nearly five times the risk of ischemic optic neuropathy (NAION), a rare eye stroke that can cause sudden vision loss, compared to Ozempic, despite both containing semaglutide. The signal was strongest in men using Wegovy, with odds roughly three times higher than in women. The European Medicines Agency already classified NAION as a very rare side effect of semaglutide in June 2025.
Read full story →FDA Issues Warning Letter to 503B Compounding Pharmacy Still Making Tirzepatide After Shortage Ended
TLDR: On May 18, the FDA issued a warning letter to a 503B outsourcing facility that continued compounding tirzepatide after the drug shortage designation was officially lifted. The action underscores the agency's ongoing enforcement push against compounders who have not wound down GLP-1 production as required. The warning comes alongside the FDA's broader April 30 proposal to formally remove semaglutide and tirzepatide from the 503B Bulks List.
Read full story →EASO Updates Obesity Guidelines, Giving Tirzepatide and Semaglutide Distinct Clinical Roles
TLDR: At the 33rd European Congress on Obesity in Malaga, the European Association for the Study of Obesity released an updated clinical algorithm that separates tirzepatide and semaglutide by indication rather than treating them as interchangeable. Tirzepatide is now preferred for maximum weight loss, while semaglutide is highlighted for patients with liver fibrosis or MASH. The update reflects accumulating head-to-head and disease-specific data.
Read full story →CMS BALANCE Model Expands Medicaid GLP-1 Coverage Starting May 2026
TLDR: The CMS BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model begins expanding GLP-1 medication access to Medicaid beneficiaries for weight management starting in May 2026, with negotiated pricing from manufacturers. The voluntary model complements the Medicare GLP-1 Bridge, which launches July 1 at a $50 monthly copay for Medicare Part D enrollees. Together, the programs could extend subsidized access to millions of low-income Americans who currently lack coverage for obesity treatment.
Read full story →Saturday — Saturday, May 23, 2026
4 articlesGLP-1 Weight-Loss Drugs Significantly Slash Heart Attack and Stroke Risk, Major Review Finds
TLDR: A meta-analysis of 11 large clinical trials covering more than 90,000 patients found that GLP-1 receptor agonists reduce major cardiovascular events by about 13%, including heart attacks, strokes, heart failure, and premature death. Benefits were consistent across different drugs and patient groups, regardless of whether patients had diabetes.
Read full story →FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Compounding List
TLDR: The FDA announced a proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound these drugs. This would effectively end large-scale compounding of GLP-1 drugs by 503B outsourcing facilities. Public comments are open through June 29, 2026.
Read full story →Medicare GLP-1 Bridge Program Offers $50 Monthly Copay Starting July 2026
TLDR: CMS announced a short-term demonstration called the Medicare GLP-1 Bridge, running July 1, 2026 through December 31, 2027. Eligible beneficiaries can access Foundayo, Wegovy, or Zepbound at a flat $50 monthly copayment that does not increase with dose escalation.
Read full story →Oral GLP-1 Pill Helps Patients Maintain Weight Loss After Stopping Injectables, Trial Shows
TLDR: The ATTAIN-MAINTAIN phase 3b trial, published May 12 in Nature Medicine, found that switching from injectable GLP-1s to the oral pill orforglipron allowed patients to maintain 75-80% of their weight loss and cardiometabolic benefits over 52 weeks. The 376-patient trial was led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Read full story →Friday — Friday, May 22, 2026
4 articlesGLP-1 Drugs Cut Heart Attack and Stroke Risk by 13%, Major Review Finds
TLDR: A systematic review of 11 major cardiovascular outcome trials involving over 90,000 patients found that GLP-1 receptor agonists reduced the risk of heart attacks, strokes, and cardiovascular death by about 13%. Researchers at Anglia Ruskin University found the benefits held regardless of whether patients had diabetes, and all-cause mortality was also lower. The findings were published in Cardiovascular Diabetology – Endocrinology Reports.
Read full story →Oral GLP-1 Pill Helps Patients Maintain 75–80% of Weight Loss After Stopping Injectables
TLDR: The ATTAIN-MAINTAIN trial found that patients who switched from injectable GLP-1s (tirzepatide or semaglutide) to the oral pill orforglipron maintained 75–80% of their weight loss over 52 weeks. Led by Weill Cornell Medicine and NewYork-Presbyterian, the phase 3b trial enrolled 376 patients and was published May 12 in Nature Medicine. The pill was well-tolerated, with only mild to moderate GI side effects.
Read full story →FDA Proposes Removing Semaglutide, Tirzepatide, and Liraglutide from 503B Compounding List
TLDR: The FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The move would effectively end large-scale compounding of GLP-1 medications at most facilities, with a public comment period closing June 29, 2026. If finalized, the already-reduced supply of compounded GLP-1s would drop sharply.
Read full story →Medicare Launches Bridge Program to Lower GLP-1 Co-Pays for Seniors
TLDR: The Trump administration has rolled out a Medicare bridge program designed to reduce out-of-pocket GLP-1 costs for eligible seniors, creating a new pathway to coverage for obesity drugs like Wegovy and Zepbound. Medicare has historically excluded weight-loss drugs, and the pilot program is being watched closely as a potential model for broader coverage expansion. Details on eligibility and co-pay levels are still being finalized.
Read full story →Thursday — Thursday, May 21, 2026
4 articlesFDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Compounding List
TLDR: The FDA announced it is proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The move effectively moves to close the door permanently on large-scale compounding of these GLP-1 medications. Public comments are open through June 29, 2026.
Read full story →Oral GLP-1 Pill Orforglipron Helps Patients Keep Weight Off After Stopping Injectables
TLDR: A phase 3b clinical trial (ATTAIN-MAINTAIN) found that switching from injectable GLP-1s to once-daily oral orforglipron helped patients maintain roughly 75-80% of their prior weight loss over 52 weeks. The study, published in Nature Medicine, is the first to examine longer-term weight maintenance using an oral GLP-1 after injectable therapy and offers a potential new option for patients who want to avoid injections.
Read full story →Semaglutide Delivers Major Weight Loss in Adults Over 65, Large Analysis Finds
TLDR: A pooled analysis of six STEP clinical trials found that semaglutide produced an average body weight reduction of 15.4% in adults over age 65 with obesity — nearly triple the 5.1% seen with placebo. Presented at ECO 2026, the findings support the use of GLP-1 therapy in older adults, a population where obesity-related complications are especially prevalent.
Read full story →Medicare GLP-1 Bridge Program to Launch July 2026 with $50 Monthly Copay
TLDR: CMS has finalized the Medicare GLP-1 Bridge, a short-term coverage demonstration running July 1, 2026 through December 31, 2027. Eligible Medicare Part D beneficiaries can access Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay, with CMS covering the remaining cost. The program has been extended through 2027 following adjustments by the Trump administration.
Read full story →Wednesday — Wednesday, May 20, 2026
4 articlesGreater Weight Loss on GLP-1s Dramatically Cuts Risk of Sleep Apnea, Kidney Disease, and Heart Failure
TLDR: A real-world study of nearly 90,000 patients found that those who lost 15% or more of their BMI on GLP-1 medications had a 69% lower risk of sleep apnea, 37% lower risk of osteoarthritis, and 30% lower risk of chronic kidney disease. Presented at ECO 2026, the findings underscore the clinical value of sustained weight loss. Roughly half of all patients discontinued treatment within one year.
Read full story →Switching from Injectable GLP-1 to Orforglipron Pill Preserves Most Weight Loss, Phase 3 Trial Finds
TLDR: The ATTAIN-MAINTAIN trial showed that patients who switched from injectable semaglutide or tirzepatide to Lilly's oral orforglipron (Foundayo) maintained 75-80% of their weight loss over 52 weeks. Published May 12 in Nature Medicine, the results position orforglipron as a practical long-term maintenance option for patients who want to avoid ongoing injections.
Read full story →FDA Proposes Permanent Ban on Bulk Compounding of Semaglutide and Tirzepatide
TLDR: The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would permanently bar outsourcing facilities from compounding these drugs from bulk ingredients. The public comment period closes June 29, 2026. The move follows more than 455 adverse event reports linked to compounded semaglutide products.
Read full story →Medicare to Launch $50/Month GLP-1 Weight Loss Drug Bridge Program Starting July 2026
TLDR: CMS announced that Medicare Part D beneficiaries will gain access to GLP-1 weight loss drugs for a $50 monthly copay starting July 1, 2026, through December 2027. The temporary bridge program represents a major shift in coverage for millions of Medicare enrollees and is intended to bridge the gap before permanent coverage decisions are finalized.
Read full story →Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.